| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print September 4, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



From the Division of Rheumatology,* Northwestern University Feinberg School of Medicine, Chicago, Illinois; the Department of Dermatology,
Kanazawa University, Kanazawa, Japan; and the Division of Pulmonary Medicine,
University of Pittsburgh, Pittsburgh, Pennsylvania
Transforming growth factor-β (TGF-β) plays a key role in scleroderma pathogenesis. The transcription factor early growth response-1 (Egr-1) mediates the stimulation of collagen transcription elicited by TGF-β and is necessary for the development of pulmonary fibrosis in mice. Here, we report that TGF-β causes a time- and dose-dependent increase in Egr-1 protein and mRNA levels and enhanced transcription of the Egr-1 gene via serum response elements in normal fibroblasts. The ability of TGF-β to stimulate Egr-1 was preserved in Smad3-null mice and in explanted Smad3-null fibroblasts. The response was blocked by a specific mitogen-activated protein kinase kinase 1 (MEK1) inhibitor but not by an ALK5 kinase inhibitor. Furthermore, MEK1 was phosphorylated by TGF-β, which was sufficient to drive Egr-1 transactivation. Stimulation by TGF-β enhanced the transcriptional activity of Elk-1 via the MEK-extracellular signal-regulated kinase 1/2 pathway. Bleomycin-induced scleroderma in the mouse was accompanied by increased Egr-1 accumulation in lesional fibroblasts. Furthermore, biopsies of lesional skin and lung from patients with scleroderma showed increased Egr-1 levels, which were highest in early diffuse disease. Moreover, both Egr-1 mRNA and protein were elevated in explanted scleroderma skin fibroblasts in vitro. Together, these findings define a Smad-independent TGF-β signal transduction mechanism that underlies the stimulation of Egr-1, demonstrate for the first time sustained Egr-1 up-regulation in fibrotic lesions and suggests that Egr-1 has a role in the induction and progression of fibrosis.
This article has been cited by other articles:
![]() |
M. Wu, D. S. Melichian, M. de la Garza, K. Gruner, S. Bhattacharyya, L. Barr, A. Nair, S. Shahrara, P. H.S. Sporn, T. A. Mustoe, et al. Essential Roles for Early Growth Response Transcription Factor Egr-1 in Tissue Fibrosis and Wound Healing Am. J. Pathol., September 1, 2009; 175(3): 1041 - 1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yasuoka, E. Hsu, X. D. Ruiz, R. A. Steinman, A. M.K. Choi, and C. A. Feghali-Bostwick The Fibrotic Phenotype Induced by IGFBP-5 Is Regulated by MAPK Activation and Egr-1-Dependent and -Independent Mechanisms Am. J. Pathol., August 1, 2009; 175(2): 605 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, and J. Varga Rosiglitazone Abrogates Bleomycin-Induced Scleroderma and Blocks Profibrotic Responses Through Peroxisome Proliferator-Activated Receptor-{gamma} Am. J. Pathol., February 1, 2009; 174(2): 519 - 533. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |